Bruce Strober1, Chitra Karki2, Marc Mason2, Ning Guo2, Stacey H Holmgren2, Jeffrey D Greenberg3, Mark Lebwohl4. 1. University of Connecticut Health Center, Farmington, Connecticut; Probity Medical Research, Waterloo, Ontario, Canada. Electronic address: strober@uchc.edu. 2. Corrona LLC, Southborough, Massachusetts. 3. Corrona LLC, Southborough, Massachusetts; NYU School of Medicine, New York, New York. 4. Icahn School of Medicine at Mount Sinai, New York, New York.
Abstract
BACKGROUND: Psoriasis is an immunodysregulatory inflammatory disease associated with comorbidities affecting quality of life. With the advent of new treatments, there is growing need to assess the long-term safety and efficacy of treatments in a real-world setting. OBJECTIVE: The objective of the Corrona Psoriasis Registry is to study the comparative safety and efficacy of Food and Drug Administration-approved biologic treatments. METHODS: A cross-sectional study of patients enrolled in the registry, who initiated or switched to a systemic therapy at enrollment or previous 12 months. Descriptive characteristics (demographics, clinical and patient-reported outcomes, comorbidities, and treatment history) were examined at registry enrollment. RESULTS: As of October 1, 2016, there were 1942 patients enrolled in the registry: 23% on apremilast, 4% on other nonbiologic systemic medications, 25% on interleukin (IL) 17A inhibitors, 22% on an IL-12/23 inhibitor, and 26% on tumor necrosis factor inhibitors. Overall, mean disease duration was 15.6 years, and 40% had a concurrent psoriatic arthritis diagnosis. About 66% had >3% body surface area involvement and 49% had a moderate or severe Investigator Global Assessment. LIMITATIONS: Selection and channeling bias can result in potential confounding that needs to be addressed in modeled analyses. CONCLUSION: This disease-based registry cohort represents a population exposed to multiple therapies, long disease duration, and multiple comorbidities and can be used to examine comparative safety and efficacy of various therapies.
BACKGROUND: Psoriasis is an immunodysregulatory inflammatory disease associated with comorbidities affecting quality of life. With the advent of new treatments, there is growing need to assess the long-term safety and efficacy of treatments in a real-world setting. OBJECTIVE: The objective of the Corrona Psoriasis Registry is to study the comparative safety and efficacy of Food and Drug Administration-approved biologic treatments. METHODS: A cross-sectional study of patients enrolled in the registry, who initiated or switched to a systemic therapy at enrollment or previous 12 months. Descriptive characteristics (demographics, clinical and patient-reported outcomes, comorbidities, and treatment history) were examined at registry enrollment. RESULTS: As of October 1, 2016, there were 1942 patients enrolled in the registry: 23% on apremilast, 4% on other nonbiologic systemic medications, 25% on interleukin (IL) 17A inhibitors, 22% on an IL-12/23 inhibitor, and 26% on tumornecrosis factor inhibitors. Overall, mean disease duration was 15.6 years, and 40% had a concurrent psoriatic arthritis diagnosis. About 66% had >3% body surface area involvement and 49% had a moderate or severe Investigator Global Assessment. LIMITATIONS: Selection and channeling bias can result in potential confounding that needs to be addressed in modeled analyses. CONCLUSION: This disease-based registry cohort represents a population exposed to multiple therapies, long disease duration, and multiple comorbidities and can be used to examine comparative safety and efficacy of various therapies.
Authors: Giovanni Damiani; Rosalynn R Z Conic; Valerio de Vita; Antonio Costanzo; Roberto Regazzini; Paolo D M Pigatto; Nicola L Bragazzi; Alessia Pacifico; Piergiorgio Malagoli Journal: Dermatol Ther Date: 2018-12-21 Impact factor: 2.851
Authors: P Borsky; Z Fiala; C Andrys; M Beranek; K Hamakova; J Kremlacek; A Malkova; T Svadlakova; J Krejsek; V Palicka; V Rehacek; L Kotingova; L Borska Journal: Physiol Res Date: 2021-05-12 Impact factor: 1.881
Authors: Benjamin Lockshin; Angel Cronin; Ryan W Harrison; Robert R McLean; Laura Anatale-Tardiff; Russel Burge; Baojin Zhu; William N Malatestinic; Bilal Atiya; Mwangi J Murage; Gaia Gallo; Bruce Strober; Abby Van Voorhees Journal: Dermatol Ther Date: 2021-02-15 Impact factor: 2.851
Authors: Giovanni Damiani; Nicola Luigi Bragazzi; Chante Karimkhani Aksut; Dongze Wu; Gianfranco Alicandro; Dennis McGonagle; Cui Guo; Robert Dellavalle; Ayman Grada; Priscilla Wong; Carlo La Vecchia; Lai-Shan Tam; Kevin D Cooper; Mohsen Naghavi Journal: Front Med (Lausanne) Date: 2021-12-16
Authors: Jessica A Walsh; Kristina Callis Duffin; Abby S Van Voorhees; Soumya D Chakravarty; Timothy Fitzgerald; Amanda Teeple; Katelyn Rowland; Jonathan Uy; Robert R McLean; Wendi Malley; Angel Cronin; Joseph F Merola Journal: Dermatol Ther (Heidelb) Date: 2021-11-25
Authors: Sameerah Nawaz; Amanda Tapley; Andrew R Davey; Mieke L van Driel; Alison Fielding; Elizabeth G Holliday; Jean Ball; Irena Patsan; Alyse Berrigan; Simon Morgan; Neil A Spike; Kristen FitzGerald; Parker Magin Journal: Dermatol Pract Concept Date: 2021-05-20
Authors: Mark G Lebwohl; Andrew Blauvelt; Alan Menter; Kim A Papp; Scott Guenthner; Radhakrishnan Pillai; Robert J Israel; Abby Jacobson Journal: Am J Clin Dermatol Date: 2019-12 Impact factor: 7.403